Supernus Pharmaceuticals
Develops CNS medicines spanning ADHD, Parkinson’s disease, postpartum depression, and epilepsy.
Something off on this page? Send us feedback.
Profile
Develops and commercializes CNS medicines for ADHD, Parkinson’s disease, postpartum depression, epilepsy, and other movement disorders. Revenue comes primarily from U.S. product sales, with ZURZUVAE adding collaboration revenue through Biogen and the business operating as a single segment.
Develops and commercializes medicines for central nervous system disorders, with marketed products spanning ADHD, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Core brands include Qelbree, GOCOVRI, ZURZUVAE, ONAPGO, APOKYN, Oxtellar XR, Trokendi XR, XADAGO, and MYOBLOC.
Pairs drug-formulation and clinical-development capabilities with acquisitions and dedicated U.S. sales teams for ADHD, movement disorders, and postpartum depression. Revenue comes mainly from U.S. product sales; ZURZUVAE contributes collaboration revenue under a shared U.S. commercialization arrangement with Biogen.
Operates as one segment and outsources commercial manufacturing, while a concentrated wholesaler and distributor base accounts for most product revenue and specialty pharmacies carry several key brands. A pending all-stock merger with Indivior requires shareholder and regulatory approvals; the combined company is expected to retain the Supernus name and SUPN ticker.
Company facts
Key statistics
Year to date −11.5% · Average volume (30d) 860.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Craig-Hallum | Target | $65 | |||
| Dec 19, 2025 | Stifel Nicolaus | Target | $38 | $55 | ||
| Oct 9, 2025 | Piper Sandler | Upgrade | Neutral | Overweight | ||
| Oct 8, 2025 | Piper Sandler | Target | $40 | $65 | ||
| Sep 30, 2025 | Cantor Fitzgerald | Reiterate | Overweight | $42 | $63 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | $0.42 | $0.54 | +27.8% | $205.3M | $219.1M | +6.7% | −5.98% |
| May 5, 2026Q1 FY26 | $0.28 | $0.59 | +110.7% | $192.9M | $207.7M | +7.7% | +4.59% |
| Feb 24, 2026Q4 FY25 | $0.28 | $0.92 | +228.6% | $195.2M | $211.6M | +8.4% | +5.67% |
| Nov 4, 2025Q3 FY25 | $0.82 | $1.01 | +23.2% | $194.7M | $192.1M | −1.3% | −17.35% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $149.8M | $165.5M | $192.1M | $211.6M | $207.7M | $219.1M | |
| Gross profit | $134.1M | $148.6M | $173.1M | $188.6M | $184.3M | $185.4M | |
| Operating income | −$10.3M | $12.1M | −$60.2M | $13.8M | −$7.4M | −$58.0M | |
| Net income | −$11.8M | $22.5M | −$45.1M | −$4.1M | −$2.3M | −$58.4M | |
| Diluted EPS | −$0.21 | $0.40 | −$0.80 | −$0.07 | −$0.04 | −$1.01 | |
| Gross margin | 89.5% | 89.8% | 90.1% | 89.1% | 88.7% | 84.6% | |
| Operating margin | -6.8% | 7.3% | -31.4% | 6.5% | -3.6% | -26.5% |
Fiscal years (4-quarter sums)FY21 $579.8M · FY22 $667.2M · FY23 $607.5M · FY24 $661.8M · FY25 $719.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $372.1M · Total debt $40.2M · Total assets $1.43B · Shareholders' equity $1.03B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 58.04M · Float 54.44M · 93.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.35M | 16.11% | 13F | Aug 7, 2026 |
| Millennium Management LLC | 3.85M | 6.64% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 3.31M | 5.70% | 13F | Aug 13, 2026 |
| Armistice Capital, LLC | 2.65M | 4.56% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.52M | 4.34% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 17, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −50,000 | $50.30 |
| Mar 18, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −7,250 | $49.60 |
| Mar 16, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −50,000 | $50.28 |
| Mar 12, 2026 | Frederick M. Hudson | director | −5,369 | $50.61 |
| Mar 13, 2026 | Jack A. Khattar | director, officer: President, CEO | −35,000 | $50.37 |
Peers
- Takeda (ADR)
ADHD stimulant benchmark with Vyvanse and Shire-era scale
- AbbVie
Direct Parkinson's infusion rival through VYALEV and Duopa
- Johnson & Johnson
Concerta keeps a major stimulant alternative in ADHD
- Amneal Pharmaceuticals
Parkinson's specialty peer with CREXONT, RYTARY, and ONGENTYS
- Teva (ADR)
Generic ADHD and CNS pressure across branded franchises
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals | $44.58 | +1.87% | $2.54B | — | 15.1 | 3.1 | +32.4% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Median | 51.0 | 16.9 | 2.5 | +6.6% |